CFDB - Cystic Fibrosis DataBase

at least one term
all terms
All subcategories » Health Technology Assessment Report

Lumacaftor/ivacaftor - assessment according to §35a (para. 1, sentence 10) Social Code Book V (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2016
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

Ivacaftor - assessment according to §35a (para. 1, sentence 10) Social Code Book V (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2016
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

High-frequency chest wall compression for cystic fibrosis

HTA -  Health Technology Assessment Report

Details
  • 2016
  • HAYES

Lumacaftor-ivacaftor (Orkambi) for treatment of cystic fibrosis (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2015
  • HAYES

Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2015
  • Hernández-Vásquez A

Ataluren (Translarna) for CFTR class I nonsense mutation mediated cystic fibrosis (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2015
  • NIHR HSRIC

Ivacaftor - assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment) (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2014
  • IQWiG

Lumacaftor and ivacaftor combination therapy for cystic fibrosis ? first line (Structured abstract)

HTA -  Health Technology Assessment Report

Details
  • 2014
  • NIHR HSC

Ivacaftor (Kalydeco) for an additional 8 mutations in cystic fibrosis (licence extension)

HTA -  Health Technology Assessment Report

Details
  • 2014
  • NIHR HSC

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.

HTA -  Health Technology Assessment Report

Details
  • 2014
  • Whiting P